Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 296

Related Citations for PubMed (Select 22939887)

1.

Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.

Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG.

J Steroid Biochem Mol Biol. 2013 Jan;133:30-42. doi: 10.1016/j.jsbmb.2012.08.004. Epub 2012 Aug 23.

PMID:
22939887
2.
3.

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.

Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B, Serrero G.

BMC Cancer. 2011 Jun 9;11:231. doi: 10.1186/1471-2407-11-231.

4.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

5.
6.

Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.

Moy I, Lin Z, Rademaker AW, Reierstad S, Khan SA, Bulun SE.

PLoS One. 2013 Nov 6;8(11):e77543. doi: 10.1371/journal.pone.0077543. eCollection 2013.

7.

Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S.

Mol Cancer Res. 2005 Apr;3(4):203-18.

8.

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.

Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S.

Cancer Res. 2008 Jun 15;68(12):4910-8. doi: 10.1158/0008-5472.CAN-08-0303.

9.

The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.

Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S.

Breast Cancer Res Treat. 2010 Nov;124(1):89-99. doi: 10.1007/s10549-009-0716-3. Epub 2010 Jan 7.

10.

Synergistic activity of letrozole and sorafenib on breast cancer cells.

Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG.

Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.

PMID:
20054642
11.

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, Johnston SR, Dowsett M, Martin LA.

Br J Cancer. 2010 Apr 13;102(8):1235-43. doi: 10.1038/sj.bjc.6605641.

12.

Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.

Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237. Epub 2014 Nov 23.

PMID:
25421723
13.

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102.

14.

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.

Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.

PMID:
23553037
15.

Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.

Wang J, Gildea JJ, Yue W.

Oncogene. 2013 Oct 31;32(44):5233-40. doi: 10.1038/onc.2012.558. Epub 2012 Nov 26.

PMID:
23178495
16.

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.

Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15.

PMID:
22985911
17.

AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.

Wong C, Wang X, Smith D, Reddy K, Chen S.

Breast Cancer Res Treat. 2012 Jul;134(2):671-81. doi: 10.1007/s10549-012-2105-6. Epub 2012 Jun 16.

18.

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.

19.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
20.

AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.

O'Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, Hill AD, McIlroy M, Young LS.

Clin Cancer Res. 2012 Jun 15;18(12):3305-15. doi: 10.1158/1078-0432.CCR-11-3300. Epub 2012 May 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk